Abstract：
A randomized control trial was performed over a five-year period to assess the efficacy and antibody response induced by autogenous and commercial vaccine formulations against infectious bovine keratoconjunctivitis (IBK). Calves were randomly assigned each year to one of three arms: an autogenous vaccine treatment that included Moraxella bovis (M. bovis), Moraxella bovoculi, and Mycoplasma bovoculi antigens, a commercial M. bovis vaccine treatment, or a sham vaccine treatment that consisted only of adjuvant. A total of 1198 calves were enrolled in the study. Calves were administered the respective vaccines approximately 21 days apart, just prior to turnout on summer pastures. Treatment effects were analyzed for IBK incidence, retreatment incidence, 205-day adjusted weaning weights, and antibody response to the type IV pilus protein (pili) of M. bovis as measured by a novel indirect enzyme-linked immunosorbent screening assay (ELISA). Calves vaccinated with the autogenous formulation experienced a decreased cumulative incidence of IBK over the entire study compared to those vaccinated with the commercial and sham formulations (24.5% vs. 30.06% vs. 30.3%, respectively, p = 0.25), and had less IBK cases that required retreatment compared to the commercial and sham formulations (21.4% vs. 27.9% vs. 34.3%, respectively, p = 0.15), but these differences were not significant. The autogenous formulation induced a significantly stronger antibody response than the commercial (p = 0.022) and sham formulations (p = 0.001), but antibody levels were not significantly correlated with IBK protection (p = 0.37).
摘要：
进行了为期五年的随机对照试验，以评估自体和商业疫苗制剂针对传染性牛角膜结膜炎（IBK）的功效和抗体反应。小牛每年被随机分配到三个组之一：包括牛莫拉氏菌的自体疫苗治疗（M。bovis),Bovoculi莫拉菌,和结核支原体抗原,商业牛分枝杆菌疫苗治疗，或仅由佐剂组成的假疫苗治疗。总共1198头小牛被纳入研究。每隔大约21天，小牛接种各自的疫苗，就在夏季牧场投票之前。分析IBK发病率的治疗效果，再治疗发生率，205天调整的断奶体重，和通过新型间接酶联免疫吸附筛选测定法（ELISA）测量的对牛分枝杆菌IV型菌毛蛋白（菌毛）的抗体反应。与用商业和假制剂接种的小牛相比，用自体制剂接种的小牛在整个研究中IBK的累积发生率降低(24.5%vs.30.06%vs.30.3%,分别,p=0.25),与商业和假制剂相比，需要再治疗的IBK病例较少(21.4%vs.27.9%与34.3%,分别,p=0.15),但这些差异并不显著。自体制剂诱导明显强于商业(p=0.022)和假制剂(p=0.001)的抗体应答,但是抗体水平与IBK保护没有显着相关（p=0.37）。
